Soluble ST2: A Novel Biomarker for Diagnosis and Prognosis of Cardiovascular Disease

Abstract

The increasing incidence of cardiovascular disease (CVD) is a significant global health concern, affecting millions of individuals each year. Accurate diagnosis of acute CVD poses a formidable challenge, as misdiagnosis can significantly decrease patient survival rates. Traditional biomarkers have played a vital role in the diagnosis and prognosis of CVDs, but they can be influenced by various factors, such as age, sex, and renal function. Soluble ST2 (sST2) is a novel biomarker that is closely associated with different CVDs. Its low reference change value makes it suitable for continuous measurement, unaffected by age, kidney function, and other confounding factors, facilitating risk stratification of CVDs. Furthermore, the combination of sST2 with other biomarkers can enhance diagnostic accuracy and prognostic value. This review aims to provide a comprehensive overview of sST2, focusing on its diagnostic and prognostic value as a myocardial marker for different types of CVDs and discussing the current limitations of sST2.

References

[1] Zhao D, Liu J, Wang M, et al.. Epidemiology of cardiovascular disease in China: current features and implications. Nature reviews. Cardiology, 2019, 16(4): 203-212

[2] Bayes-Genis A, de Antonio M, Galán A, et al.. Combined use of high-sensitivity st2 and ntprobnp to improve the prediction of death in heart failure. Eur J Heart Fail, 2012, 14(1): 32-38

[3] Villacorta H, Maisel AS. Soluble st2 testing: a promising biomarker in the management of heart failure. Arq Bras Cardiol, 2016, 106(2): 145-152

[4] Bi J, Garg V, Yates AR. Galectin-3 and sst2 as prognosticators for heart failure requiring extracorporeal life support: jack n’ jill. Biomolecules (Basel, Switzerland), 2021, 11(2): 166

[5] Daniels LB, Clopton P, Iqbal N, et al.. Association of st2 levels with cardiac structure and function and mortality in outpatients. Am Heart J, 2010, 160(4): 721-728

[6] Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, et al.. Soluble st2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol, 2009, 54(23): 2174-2179

[7] Gawor M, Spiewak M, Janas J, et al.. The usefulness of sst2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Kardiol Pol, 2017, 75(10): 997-1004

[8] Kakkar R, Lee RT. The il-33/st2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov, 2008, 7(10): 827-840

[9] Mueller T, Jaffe AS. Soluble st2—analytical considerations. Am J Cardiol, 2015, 115(7Suppl): 8B-21B

[10] Homsak E, Gruson D. Soluble st2: a complex and diverse role in several diseases. Clin Chim Acta, 2020, 507: 75-87

[11] Ragusa R, Prontera C, Di Molfetta A, et al.. Time-course of circulating cardiac and inflammatory biomarkers after ventricular assist device implantation: comparison between paediatric and adult patients. Clin Chim Acta, 2018, 486: 88-93

[12] Wang J, He M, Li H, et al.. Soluble st2 is a sensitive and specific biomarker for fulminant myocarditis. J Am Heart Assoc, 2022, 11(7): e24417

[13] Morello F, Bartalucci A, Bironzo M, et al.. Prospective diagnostic accuracy study of plasma soluble st2 for diagnosis of acute aortic syndromes. Sci Rep, 2020, 10(1): 3103

[14] Tominaga S. A putative protein of a growth specific cdna from balb/c-3t3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett, 1989, 258(2): 301-304

[15] Pascual-Figal DA, Januzzi JL. The biology of st2: the international st2 consensus panel. Am J Cardiol, 2015, 115(7Suppl): 3B-7B

[16] Iwahana H, Yanagisawa K, Ito Kosaka A, et al.. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem, 1999, 264(2): 397-406

[17] Weinberg EO, Shimpo M, De Keulenaer GW, et al.. Expression and regulation of st2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation, 2002, 106(23): 2961-2966

[18] Schmitter D, Cotter G, Voors AA. Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev, 2014, 19(3): 369-381

[19] Schmitz J, Owyang A, Oldham E, et al.. Il-33, an interleukin-1-like cytokine that signals via the receptor-related protein st2 and induces t helper type 2-associated cytokines. Immunity, 2005, 23(5): 479-490

[20] De la Fuente M, MacDonald TT, Hermoso MA. The il-33/st2 axis: role in health and disease. Cytokine Growth Factor Rev, 2015, 26(6): 615-623

[21] Vianello E, Dozio E, Tacchini L, et al.. St2/il-33 signaling in cardiac fibrosis. Int J Biochem Cell Biol, 2019, 116: 105619

[22] Weinberg EO. St2 protein in heart disease: from discovery to mechanisms and prognostic value. Biomark Med, 2009, 3(5): 495-511

[23] Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. Il-33/st2 axis in organ fibrosis. Front Immunol, 2018, 9: 2432

[24] Miller AM, Liew FY. The il-33/st2 pathway—a new therapeutic target in cardiovascular disease. Pharmacol Ther, 2011, 131(2): 179-186

[25] Seki K, Sanada S, Kudinova AY, et al.. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through st2 signaling. Circ Heart Fail, 2009, 2(6): 684-691

[26] Savarimuthu S, Goel P, Harky A. Soluble st2: a valuable prognostic marker in heart failure. Heart Fail Rev, 2022, 27(6): 2155-2164

[27] Sanada S, Hakuno D, Higgins LJ, et al.. Il-33 and st2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest, 2007, 117(6): 1538-1549

[28] Mebazaa A, Di Somma S, Maisel AS, et al.. St2 and multimarker testing in acute decompensated heart failure. Am J Cardiol, 2015, 115(7Suppl): 38B-43B

[29] Bartunek J, Delrue L, Van Durme F, et al.. Non-myocardial production of st2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol, 2008, 52(25): 2166-2174

[30] Pascual-Figal DA, Perez-Martinez MT, Asensio-Lopez MC, et al.. Pulmonary production of soluble st2 in heart failure. Circ Heart Fail, 2018, 11(12): e5488

[31] Jin Y, Wei S, Yao L. Diagnostic performance of mir-214, bnp, nt-probnp and soluble st2 in acute heart failure. Int J Clin Pract, 2021, 75(10): e14643

[32] Januzzi JL, Peacock WF, Maisel AS, et al.. Measurement of the interleukin family member st2 in patients with acute dyspnea: results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study. J Am Coll Cardiol, 2007, 50(7): 607-613

[33] Januzzi JL, Mebazaa A, Di Somma S. St2 and prognosis in acutely decompensated heart failure: the international st2 consensus panel. Am J Cardiol, 2015, 115(7Suppl): 26B-31B

[34] Aimo A, Vergaro G, Ripoli A, et al.. Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail, 2017, 5(4): 287-296

[35] Maisel AS, Richards AM, Pascual-Figal D, et al.. Serial st2 testing in hospitalized patients with acute heart failure. Am J Cardiol, 2015, 115(7Suppl): 32B-37B

[36] Manzano-Fernandez S, Januzzi JL, Pastor-Perez FJ, et al.. Serial monitoring of soluble interleukin family member st2 in patients with acutely decompensated heart failure. Cardiology, 2012, 122(3): 158-166

[37] Tang WH, Wu Y, Grodin JL, et al.. Prognostic value of baseline and changes in circulating soluble st2 levels and the effects of nesiritide in acute decompensated heart failure. JACC Heart Fail, 2016, 4(1): 68-77

[38] Xu S, Su G, Lu Y, et al.. Elevated soluble st2 and depression increased the risk of all-cause mortality and hospitalization in patients with heart failure. Int Heart J, 2014, 55(5): 445-450

[39] Januzzi JL, van Kimmenade R, Lainchbury J, et al.. Ntprobnp testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of nt-probnp study. Eur Heart J, 2006, 27(3): 330-337

[40] Homsak E, Ekart R. St2 as a novel prognostic marker in endstage renal disease patients on hemodiafiltration. Clin Chim Acta, 2018, 477: 105-112

[41] Pascual-Figal DA, Bayes-Genis A, Asensio-Lopez MC, et al.. The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure. J Am Coll Cardiol, 2019, 73(9): 1016-1025

[42] Li J, Cao T, Wei Y, et al.. A review of novel cardiac biomarkers in acute or chronic cardiovascular diseases: the role of soluble st2 (sST2), lipoprotein-associated phospholipase a2 (Lp-PLA2), myeloperoxidase (MPO), and procalcitonin (PCT). Dis Markers, 2021, 2021: 1-10

[43] Emdin M, Aimo A, Vergaro G, et al.. Sst2 predicts outcome in chronic heart failure beyond nt-probnp and high-sensitivity troponin t. J Am Coll Cardiol, 2018, 72(19): 2309-2320

[44] Gruson D, Lepoutre T, Ahn SA, et al.. Increased soluble st2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol, 2014, 172(1): e250-e252

[45] Bayes-Genis A, de Antonio M, Vila J, et al.. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: st2 versus galectin-3. J Am Coll Cardiol, 2014, 63(2): 158-166

[46] Ky B, French B, McCloskey K, et al.. High-sensitivity st2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail, 2011, 4(2): 180-187

[47] Martini L, Mandoli GE, Pastore MC, et al.. Heart transplantation and biomarkers: a review about their usefulness in clinical practice. Front Cardiovasc Med, 2024, 11: 1336011

[48] Pascual-Figal DA, Garrido IP, Blanco R, et al.. Soluble st2 is a marker for acute cardiac allograft rejection. Ann Thorac Surg, 2011, 92(6): 2118-2124

[49] Grupper A, AbouEzzeddine OF, Maleszewski JJ, et al.. Elevated st2 levels are associated with antibody-mediated rejection in heart transplant recipients. Clin Transplant, 2018, 32(9): e13349

[50] Barutaut M, Fournier P, Peacock WF, et al.. Sst2 adds to the prognostic value of gal-3 and bnp in chronic heart failure. Acta Cardiol, 2020, 75(8): 739-747

[51] Lupon J, de Antonio M, Galan A, et al.. Combined use of the novel biomarkers high-sensitivity troponin t and st2 for heart failure risk stratification vs conventional assessment. Mayo Clin Proc, 2013, 88(3): 234-243

[52] Vergaro G, Gentile F, Aimo A, et al.. Circulating levels and prognostic cut-offs of sst2, hs-ctnt, and nt-probnp in women vs. Men with chronic heart failure. ESC Heart Fail, 2022, 9(4): 2084-2095

[53] Aimo A, Maisel AS, Castiglione V, et al.. Sst2 for outcome prediction in acute heart failure: which is the best cutoff?. J Am Coll Cardiol, 2019, 74(3): 478-479

[54] Nwabuo CC, Vasan RS. Pathophysiology of hypertensive heart disease: beyond left ventricular hypertrophy. Curr Hypertens Rep, 2020, 22(2): 11

[55] Santos M, Shah AM. Alterations in cardiac structure and function in hypertension. Curr Hypertens Rep, 2014, 16(5): 428

[56] Wei P, Liu L, Wang X, et al.. Expression of soluble st2 in patients with essential hypertension and its relationship with left ventricular hypertrophy. ESC Heart Fail, 2023, 10(1): 303-310

[57] Farcaş AD, Mocan M, Anton FP, et al.. Short-term prognosis value of sst2 for an unfavorable outcome in hypertensive patients. Dis Markers, 2020, 2020: 1-8

[58] Wu F, Li L, Wen Q, et al.. A functional variant in st2 gene is associated with risk of hypertension via interfering mir-202-3p. J Cell Mol Med, 2017, 21(7): 1292-1299

[59] Poredoš P, Kaja Ježovnik M. Markers of preclinical atherosclerosis and their clinical relevance. Vasa, 2015, 44(4): 247-256

[60] Pfetsch V, Sanin V, Jaensch A, et al.. Increased plasma concentrations of soluble st2 independently predict mortality but not cardiovascular events in stable coronary heart disease patients: 13-year follow-up of the karola study. Cardiovasc Drugs Ther, 2017, 31(2): 167-177

[61] Dieplinger B, Egger M, Haltmayer M, et al.. Increased soluble st2 predicts long-term mortality in patients with stable coronary artery disease: results from the ludwigshafen risk and cardiovascular health study. Clin Chem, 2014, 60(3): 530-540

[62] Li X, Guo D, Zhou H, et al.. Pro-inflammatory cytokines, oxidative stress and diffuse coronary reocclusions in elderly patients after coronary stenting. Cytokine, 2020, 129: 155028

[63] Bai J, Han L, Liu H. Combined use of high-sensitivity st2 and nt-probnp for predicting major adverse cardiovascular events in coronary heart failure. Ann Palliat Med, 2020, 9(4): 1976-1989

[64] Wallentin L, Eriksson N, Olszowka M, et al.. Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: a retrospective study. PLoS Med, 2021, 18(1): e1003513

[65] Gevaert AB, Boen JRA, Segers VF, et al.. Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology. Front Physiol, 2019, 10: 638

[66] Zhang Y, Zhang L, Chen Z. Effect of combining sst2/hdl-c ratio with risk factors of coronary heart disease on the detection of angina pectoris in chinese: a retrospective observational study. Cardiovasc Diagn Ther, 2023, 13(2): 345-354

[67] Schernthaner C, Lichtenauer M, Wernly B, et al.. Multibiomarker analysis in patients with acute myocardial infarction. Eur J Clin Invest, 2017, 47(9): 638-648

[68] Hartopo AB, Sukmasari I, Puspitawati I. The utility of point of care test for soluble st2 in predicting adverse cardiac events during acute care of st-segment elevation myocardial infarction. Cardiol Res Pract, 2018, 2018: 3048941

[69] Xing J, Liu J, Geng T. Predictive values of sst2 and il-33 for heart failure in patients with acute myocardial infarction. Exp Biol Med (Maywood), 2021, 246(23): 2480-2486

[70] Zhang K, Zhang X, Mi Y, et al.. Predicting value of serum soluble st2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin Med J (Engl), 2013, 126(19): 3628-3631

[71] Sabatine MS, Morrow DA, Higgins LJ, et al.. Complementary roles for biomarkers of biomechanical strain st2 and n-terminal prohormone b-type natriuretic peptide in patients with st-elevation myocardial infarction. Circulation, 2008, 117(15): 1936-1944

[72] Yu J, Oh PC, Kim M, et al.. Improved early risk stratification of patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble st2 and nt-probnp. PLoS One, 2017, 12(8): e182829

[73] Tan E, Chan SP, Liew OW, et al.. Atrial fibrillation and the prognostic performance of biomarkers in heart failure. Clin Chem, 2021, 67(1): 216-226

[74] Marino L, Romano GP, Santulli M, et al.. Soluble sst2 biomarker analysis for fibrosis development in atrial fibrillation. A case control study. Clin Ter, 2021, 172(2): 145-150

[75] Krittayaphong R, Pumprueg S, Sairat P. Soluble st2 in the prediction of heart failure and death in patients with atrial fibrillation. Clin Cardiol, 2022, 45(4): 447-456

[76] Vílchez JA, Pérez Cuellar M, Marín F, et al.. Sst2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. Eur J Clin Invest, 2015, 45(9): 899-905

[77] Mujovic N, Marinkovic M, Lenarczyk R, et al.. Catheter ablation of atrial fibrillation: an overview for clinicians. Adv Ther, 2017, 34(8): 1897-1917

[78] Fan J, Li Y, Yan Q, et al.. Higher serum sst2 is associated with increased left atrial low-voltage areas and atrial fibrillation recurrence in patients undergoing radiofrequency ablation. J Interv Card Electrophysiol, 2022, 64(3): 733-742

[79] Kalstad AA, Myhre PL, Laake K, et al.. Biomarkers of ageing and cardiac remodeling are associated with atrial fibrillation. Scand Cardiovasc J, 2021, 55(4): 213-219

[80] Andreasova T, Vranova J, Vondrakova D, et al.. Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure. J Int Med Res, 2020, 48(8): 1220747421

[81] Tan R, Yu H, Han X, et al.. Circulating soluble suppression of tumorigenicity 2 predicts recurrence after radiofrequency ablation of persistent atrial fibrillation. Front Cardiovasc Med, 2021, 8: 653312

[82] Seara JG, Melchor LG, García JR, et al.. Role of soluble st2 biomarker in predicting recurrence of atrial fibrillation after electrical cardioversion or pulmonary vein isolation. Int J Mol Sci, 2023, 24(18): 14045

[83] Liu J, Han Q, Mo D. The progress of the soluble suppression of tumorigenicity 2 (sst2) in atrial fibrillation. J Interv Card Electrophysiol, 2022, 65(3): 591-592

[84] Chen L, Chen W, Shao Y, et al.. Association of soluble suppression of tumorigenicity 2 with new-onset atrial fibrillation in acute myocardial infarction. Cardiology, 2022, 147(4): 381-388

[85] Evangelista A, Isselbacher EM, Bossone E, et al.. Insights from the international registry of acute aortic dissection: a 20-year experience of collaborative clinical research. Circulation, 2018, 137(17): 1846-1860

[86] Altara R, Ghali R, Mallat Z, et al.. Conflicting vascular and metabolic impact of the il-33/sst2 axis. Cardiovasc Res, 2018, 114(12): 1578-1594

[87] Martinez-Martinez E, Miana M, Jurado-Lopez R, et al.. A role for soluble st2 in vascular remodeling associated with obesity in rats. PLoS One, 2013, 8(11): e79176

[88] Nazerian P, Mueller C, Soeiro ADM, et al.. Diagnostic accuracy of the aortic dissection detection risk score plus d-dimer for acute aortic syndromes: the advised prospective multicenter study. Circulation, 2018, 137(3): 250-258

[89] Ranasinghe AM, Bonser RS. Biomarkers in acute aortic dissection and other aortic syndromes. J Am Coll Cardiol, 2010, 56(19): 1535-1541

[90] Wang Y, Tan X, Gao H, et al.. Magnitude of soluble st2 as a novel biomarker for acute aortic dissection. Circulation, 2018, 137(3): 259-269

[91] Jia Y, Li D, Yu J, et al.. Prognostic value of interleukin-33, sst2, myeloperoxidase, and matrix metalloproteinase-9 in acute aortic dissection. Front Cardiovasc Med, 2022, 9: 1084321

[92] Alladina JW, Levy SD, Hibbert KA, et al.. Plasma concentrations of soluble suppression of tumorigenicity-2 and interleukin-6 are predictive of successful liberation from mechanical ventilation in patients with the acute respiratory distress syndrome. Crit Care Med, 2016, 44(9): 1735-1743

[93] Konstantinides SV, Meyer G, Becattini C, et al.. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the european respiratory society (ERS). Eur Heart J, 2020, 41(4): 543-603

[94] Cohen AT, Agnelli G, Anderson FA, et al.. Venous thromboembolism (VTE) in europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost, 2007, 98(4): 756-764

[95] Samperiz LA. Clinical and radiological diagnosis of pulmonary thromboembolism. Rev Clin Esp, 2020, 20(220): 50-56

[96] Patel P, Patel P, Bhatt M, et al.. Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism. Blood Adv, 2020, 4(18): 4296-4311

[97] Zheng Y, Yang T, He J, et al.. Plasma soluble st2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension. Clin Cardiol, 2014, 37(6): 365-370

[98] Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol, 2005, 20(6): 496-501

[99] Petramala L, Concistre A, Sarlo F, et al.. Assessment of sst2 behaviors to evaluate severity/clinical impact of acute pulmonary embolism. Int J Mol Sci, 2023, 24(5): 4591

[100] Gunes H, Gunes H, Dagli M, et al.. Association of soluble st2 level with 6-month mortality and/or recurrent cardiovascular-related hospitalization in pulmonary embolism. Arq Bras Cardiol, 2024, 121(2): e20230040

[101] Galie N, Humbert M, Vachiery JL, et al.. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS): endorsed by: association for european paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Respir J, 2015, 46(4): 903-975

[102] Krittika T, Remzi B. Chronic thromboembolic pulmonary hypertension. Lung, 2022, 200(3): 283-299

[103] Kerkütlüoğlu M, Gunes H, Atilla N, et al.. Relationship between soluble st2 level and chronic thromboembolic pulmonary hypertension (CTEPH) in acute pulmonary embolism (PE) patients. Cureus, 2023, 15(7): e42449

[104] Tschope C, Cooper LT, Torre-Amione G, et al.. Management of myocarditis-related cardiomyopathy in adults. Circ Res, 2019, 124(11): 1568-1583

[105] Cooper LT, Keren A, Sliwa K, et al.. The global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. Glob Heart, 2014, 9(1): 121-129

[106] Obradovic DM, Buttner P, Rommel KP, et al.. Soluble st2 receptor: biomarker of left ventricular impairment and functional status in patients with inflammatory cardiomyopathy. Cells, 2022, 11(3): 414

[107] Coronado MJ, Bruno KA, Blauwet LA, et al.. Elevated sera sst2 is associated with heart failure in men ≤ 50 years old with myocarditis. J Am Heart Assoc, 2019, 8(2): e8968

[108] Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al.. Soluble st2, high-sensitivity troponin t- and n-terminal pro-b-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail, 2011, 13(7): 718-725

[109] Grande D, Leone M, Rizzo C, et al.. A multiparametric approach based on nt-probnp, st2, and galectin3 for stratifying one year prognosis of chronic heart failure outpatients. J Cardiovasc Dev Dis, 2017, 4(3): 9

[110] Aimo A, Januzzi JJ, Vergaro G, et al.. Circulating levels and prognostic value of soluble st2 in heart failure are less influenced by age than n-terminal pro-b-type natriuretic peptide and high-sensitivity troponin t. Eur J Heart Fail, 2020, 22(11): 2078-2088

[111] Jiang S W, Wang P, Xiang X G, et al.. Serum soluble st2 is a promising prognostic biomarker in hbv-related acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int, 2017, 16(2): 181-188

[112] Hur M, Kim H, Kim HJ, et al.. Soluble st2 has a prognostic role in patients with suspected sepsis. Ann Lab Med, 2015, 35(6): 570-577

[113] Taheri O, Mauny F, Ray P, et al.. Acute heart failure in elderly patients admitted to the emergency department with acute dyspnea: a multimarker approach diagnostic study. Eur J Emerg Med, 2023, 30(5): 347-355

[114] Mueller T, Gegenhuber A, Leitner I, et al.. Diagnostic and prognostic accuracy of galectin-3 and soluble st2 for acute heart failure. Clin Chim Acta, 2016, 463: 158-164

[115] Meijers WC, Januzzi JL, DeFilippi C, et al.. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J, 2014, 167(6): 853-860

[116] Mueller T, Zimmermann M, Dieplinger B, et al.. Comparison of plasma concentrations of soluble st2 measured by three different commercially available assays: the mbl st2 assay, the presage st2 assay, and the r&d st2 assay. Clin Chim Acta, 2012, 413(19): 1493-1494

[117] Chen J, Xiao P, Song D, et al.. Growth stimulation expressed gene 2 (st2): clinical research and application in the cardiovascular related diseases. Front Cardiovasc Med, 2022, 9: 1007450

[118] Mueller T, Dieplinger B. The presage((r)) st2 assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble st2. Expert Rev Mol Diagn, 2013, 13(1): 13-30

[119] Coglianese EE, Larson MG, Vasan RS, et al.. Distribution and clinical correlates of the interleukin receptor family member soluble st2 in the framingham heart study. Clin Chem, 2012, 58(12): 1673-1681

[120] Beetler DJ, Bruno KA, Di Florio DN, et al.. Sex and age differences in sst2 in cardiovascular disease. Front Cardiovasc Med, 2022, 9: 1073814